Clonazepam (Rivotril®) and Carbamazepine (Tegretol®) in Psychomotor Epilepsy: A Randomized Multicenter Trial

Authors

  • Bent Mikkelsen,

    Corresponding author
    1. Departments of Neurology at Hjørring Hospital, Holstebro Hospital, Aalborg Hospital South, and Vejle Hospital; Department of Clinical Neurophysiology and Epilepsy, University of Odense; and Department of Clinical Research, Roche A/S, Hvidovre, Denmark
      Department of Neurology, Hjørring Hospital, DK-9800 Hjørring, Denmark.
    Search for more papers by this author
  • Peter Berggreen,

    1. Departments of Neurology at Hjørring Hospital, Holstebro Hospital, Aalborg Hospital South, and Vejle Hospital; Department of Clinical Neurophysiology and Epilepsy, University of Odense; and Department of Clinical Research, Roche A/S, Hvidovre, Denmark
    Search for more papers by this author
  • Poul Joensen,

    1. Departments of Neurology at Hjørring Hospital, Holstebro Hospital, Aalborg Hospital South, and Vejle Hospital; Department of Clinical Neurophysiology and Epilepsy, University of Odense; and Department of Clinical Research, Roche A/S, Hvidovre, Denmark
    Search for more papers by this author
  • Ole Kristensen,

    1. Departments of Neurology at Hjørring Hospital, Holstebro Hospital, Aalborg Hospital South, and Vejle Hospital; Department of Clinical Neurophysiology and Epilepsy, University of Odense; and Department of Clinical Research, Roche A/S, Hvidovre, Denmark
    Search for more papers by this author
  • Ole Køhler,

    1. Departments of Neurology at Hjørring Hospital, Holstebro Hospital, Aalborg Hospital South, and Vejle Hospital; Department of Clinical Neurophysiology and Epilepsy, University of Odense; and Department of Clinical Research, Roche A/S, Hvidovre, Denmark
    Search for more papers by this author
  • Birgit Ohrt Mikkelsen

    1. Departments of Neurology at Hjørring Hospital, Holstebro Hospital, Aalborg Hospital South, and Vejle Hospital; Department of Clinical Neurophysiology and Epilepsy, University of Odense; and Department of Clinical Research, Roche A/S, Hvidovre, Denmark
    Search for more papers by this author

Department of Neurology, Hjørring Hospital, DK-9800 Hjørring, Denmark.

Abstract

Summary: The antiepileptic properties of carbamazepine (Tegretol®) and clonazepam (Rivotril®) were compared in a double-blind randomized study comprising 36 patients with newly diagnosed, untreated psychomotor epilepsy (partial seizures with complex symptomatology). No significant differences were found between the two drugs during the 6 months of treatment. Measurements of concentrations in plasma confirmed that the patients exceeded the accepted lower limit for therapeutic range of the drugs.

RESUME

Les propriétés anti-épileptiques de la carbamazépine (Tégrétol®) et du clonazépam (Rivotril®) ont été comparées en double-aveugle chez 36 patients présentant une épilepsie psychomotrice nouvellement diagnostiquée et non encore traitée (épilepsie avec crises partielles à sémiologie complexe). Aucune différence significative n'a été trouvée entres les deux médicaments pendant les six mois de traitement. La mesure des concentrations plasmatiques a confirmé que la limite inférieure des taux thérapeutiques était dépassée chez tous les patients pour les deux médicaments.

RESUMEN

Se compararon las propiedades anticomiciales de la carbamacepina (Tegretol®) y del clonacepan (Rivotril®) por medio de un estudio doble-ciego al azar en un grupo de 36 pacientes en los que, en fecha cercana, se había hecho un diagnóstico de epilepsía psicomotora (crisis parciales con sintomatología compleja) y que no habían recibido tratamiento previo. No se encontró ninguna diferencia entre los dos fármacos durante un periodo de tratamiento de 6 meses. Las concentraciones plasmáticas confirmaron que los pacientos toleraron niveles mayores que los que se aceptan como limites inferiores terapéuticos de estos fármacos.

ZUSAMMENFASSUNG

Die antiepileptischen Eigenschaften von Carbamezepin (Tegretol®) Und Clonazepam (Rivotril®) wurden in einer randomisierten Doppelblindstudie untersucht, die 36 Patienten mit frisch diagnostizierter unbehandelter psychomotorischer Epilepsie umfasste (Partialanfälle mit komplexer Symptomatologie). Zwischen den beiden Medikamenten wurden während einer 6-monatigen Behandlung keine signifikanten Unterschiede gefunden. Messungen der Plasmakonzentrationen bestätigten, daß die Patienten, die angenommene untere Grenze des therapeutischen Bereichs überschritten.

Ancillary